Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.46 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835414 | 1.00 | GRM5 (0.46) | GRM5F10GRM2HTR7CETP | |
| SCHEMBL2835182 | 1.00 | GRM5 (0.46) | GRM5F10GRM2HTR7CETP | |
| SCHEMBL2833729 | 0.88 | GRM5 (0.46) | GRM5F10GRM2HTR7CETP | |
| SCHEMBL2835840 | 0.88 | GRM5 (0.46) | GRM5F10GRM2HTR7CETP | |
| SCHEMBL2832993 | 0.88 | GRM5 (0.46) | GRM5F10GRM2HTR7CETP | |
| SCHEMBL3325784 | 0.84 | GRM5 (0.46) | GRM5F10GRM2 | |
| Hydrochloric Acid SCHEMBL8354006 | 0.83 | GRM5 (0.45) | GRM5F10GRM2 | |
| SCHEMBL13471891 | 0.80 | GRM5 (0.41) | GRM5F10GRM2HTR7CETP | |
| SCHEMBL13471909 | 0.80 | GRM5 (0.41) | GRM5F10GRM2HTR7CETP | |
| SCHEMBL13471908 | 0.80 | GRM5 (0.41) | GRM5F10GRM2HTR7CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166847-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2166847-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8293721-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARPE & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293721-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARPE & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293721-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARPE & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
| EP-2166847-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156718-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156718-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | GRM5 4639/4885F10 2523/4885GRM2 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.